# Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy

> **NCT03904108** · PHASE2 · TERMINATED · sponsor: **ROGER S KERESZTES MD** · enrollment: 3 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Ramucirumab

## Key facts

- **NCT ID:** NCT03904108
- **Lead sponsor:** ROGER S KERESZTES MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-27
- **Primary completion:** 2020-07-27
- **Final completion:** 2020-07-27
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** insufficient patient population to complete trial as planned
- **Last updated:** 2022-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03904108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03904108, "Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03904108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*